Merck Sees Revenue Growth Amid Keytruda and WELIREG Success

Merck & Co., Inc. (NYSE: MRK) reported its second-quarter earnings, showcasing revenue growth of 5% year-over-year to $16.6 billion. Chief Financial Officer Caroline Litchfield attributed this increase to the oncology, animal health, and newer product launches.

The company incurred a one-time charge of $2.31 per share tied to its acquisition of Terns Pharmaceuticals, which generated a $5.7 billion charge in the quarter. Merck raised and narrowed its 2026 revenue outlook to a range of $66.3 billion to $67.3 billion.

Sales from KEYTRUDA family products rose 4% to $8.4 billion, driven by uptake in earlier-stage cancers and increased utilization with PADCEV in locally advanced or metastatic urothelial cancer. WELIREG sales surged 67% to $271 million due to international launches and increased use among certain U.S. patients.